Indivior warns of bigger hit from copycat drug

Text size Aa Aa

(Reuters) - Indivior <INDV.L> said on Wednesday the impact from the launch of a generic version of its opioid addiction treatment "could be materially higher" in 2018, as the British drugmaker posted a second straight drop in quarterly profit.

The company, which issued a profit warning this month citing significant market share loss for star drug Suboxone Film, said adjusted net income fell 21.3 percent to $70 million (£53 million) in the quarter ended June 30 from a year earlier.

Revenue fell 6.9 percent to $268 million in the quarter.

(Reporting by Justin George Varghese in Bengaluru; Editing by Saumyadeb Chakrabarty)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on for a limited time.